30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
Even as they make their investment, private equity investors are focused on their exit. A standard f...
Read More >
Following a historic 2020 election, with record voter turnout and multiple controversies amid a glob...
Read More >
On February 19, 2020, the IRS published two guidance documents... of significant legal and commercia...
Read More >
California lawmakers vote to extend COVID-19 eviction protections through June - Los Angeles Times...
Read More >
Ever since China began opening up to the outside world, the right of foreign-invested enterprises ("...
Read More >
Foreign investment trust notifications, foreign investment corporation notifications, and Article 63...
Read More >